FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) NEW YORK, NY / ACCESSWIRE / July 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients… Read More »
Dr. Nahid Bhadelia, founding director of the Center for Emerging Infectious Diseases at Boston University, told CNBC, that, medically, she agrees with President Joe Biden‘s assertion that platforms like Facebook are killing people by allowing Covid-19 vaccine misinformation on their services. “I think social media is playing a big role in amplifying misinformation, which is leading… Read More »
Lyme disease affects an estimated 300,000 people in the United States each year. Despite its increasing prevalence, there are many lingering myths about this tick-borne illness. Also known as the “great imitator,” Lyme disease often affects more than one system in the body and can trigger a wide range of symptoms that may mimic other… Read More »
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes WHIPPANY, N.J.– July 9, 2021 (BUSINESS WIRE)– Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained… Read More »